This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
type-1-diabetes
Type 1 Diabetes
Autoimmune destruction of pancreatic beta cells → absolute insulin deficiency; CD8+ and CD4+ Th1 cells target GAD65, IA-2, and insulin antigens. Staged by autoantibody seropositivity; teplizumab (anti-CD3) delays clinical onset; managed with insulin replacement.
Entry Metadata
| Field | Value |
|---|---|
| ID | type-1-diabetes |
| Name | Type 1 Diabetes |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82. · PubMed 23890997
- Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613. · PubMed 31180675
- Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. · PubMed 26404926